Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics to Present at the 8th Annual IPF Summit
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.
2024年8月19日，德克薩斯州奧斯汀/美通社/--生物醫藥公司艾勒隆治療公司（"艾勒隆"）（納斯達克:ALRN）推進一系列創新藥物管線，以解決特殊小衆肺部和纖維化相關問題的重大未滿足醫療需求。今天宣佈，艾勒隆公司總裁兼首席執行官Brian Windsor博士將出席於2024年8月20日至22日在馬薩諸塞州波士頓舉行的第八屆IPF峯會，並發表演講。
Details of the presentation are as follows:
演示的詳細信息如下:
Presentation Title: Biomarker Strategies in the Clinical Development of LTI-03 in IPF
Session: Emerging Biology & Early Translation | Uncovering a Translational Framework of Preclinical Modelling to Enhance the Predictive Power & Navigate from Bench to Bedside for the Next-Gen Therapeutics
Date & Time: Wednesday, August 21, 2024, at 2:45 PM ET
演講題目:基於生物標誌物的LTI-03在IPF臨床開發中的策略
版塊:新興生物學與早期轉化|揭示基於臨床前模型的轉化框架，增強預測力並導航從實驗室到牀邊的下一代治療法
日期和時間：2024年8月21日週三下午2:45 美國東部時間
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.
IPF峯會是針對肺纖維化社區的最大藥物開發舉措，彙集了來自全球的關鍵生物醫藥公司、臨床醫師和學術研究人員。有關IPF峯會的更多信息，請訪問ipf-summit.com。
About Aileron Therapeutics
關於Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis, with Cohort 2 results expected to be reported in the third quarter this year. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Aileron Therapeutics是一家生物製藥公司，致力於開發一系列新藥管線，以解決孤兒肺和纖維化疾病領域的重大醫療需求。Aileron的主打產品候選藥物LTI-03是一種新型的合成肽，具有雙重機制，旨在促進肺泡上皮細胞的存活，同時抑制纖維化信號的傳遞。目前，LTI-03正在進行第1b期臨床試驗，用於治療特發性肺纖維化，預計第2組結果將於今年第三季度公佈。Aileron的第二個產品候選藥物LTI-01是一種前酶，已完成用於治療侷限性胸膜積液的第1b期和第2a期臨床試驗，在美國和歐盟獲得了孤兒藥物認證和美國快速通道認證。
Investor Relations & Media Contact:
Argot Partners
[email protected]
212-600-1902
投資者關係和媒體聯繫人：
阿哥特合夥人。
[email protected]
212-600-1902
SOURCE Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc的消息來源。
譯文內容由第三人軟體翻譯。